Literature DB >> 7611561

Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

T K Jha1, Y N Giri, T K Singh, S Jha.   

Abstract

Thirty-four multidrug-resistant cases of Indian visceral leishmaniasis (kala-azar) were treated with amphotericin B. A complete hemogram, liver and renal function tests, determination of serum electrolyte levels, a chest radiograph, and an electrocardiogram were done before, during, and after completion of therapy. Assessment for clinical and parasitologic cure was done weekly. Thirty-one patients who completed treatment had full cure after receiving 10-15 injections at six-months follow up. One patient died of myocarditis. A febrile reaction was observed in all cases, while thrombophlebitis was found in six cases (18.75%). Anorexia, nausea, and vomiting were found in seven cases (21.88%). No significant nephrotoxicity or electrolyte disturbances were observed. It is concluded that amphotericin B is an effective second-line drug for Indian visceral leishmaniasis, but unpredictable drug-induced myocarditis remains a problem.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7611561     DOI: 10.4269/ajtmh.1995.52.536

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani.

Authors:  Bidyut Purkait; Ashish Kumar; Nilay Nandi; Abul Hasan Sardar; Sushmita Das; Sudeep Kumar; Krishna Pandey; Vidyananda Ravidas; Manish Kumar; Tripti De; Dharmendra Singh; Pradeep Das
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

2.  A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.

Authors:  Nawin Kumar; Prabhat Kumar Sinha; Krishna Pandey; Neena Verma; Chandra Shekhar Lal; Alok Ranjan; Rakesh Bihari Verma; Pradeep Das
Journal:  Int J Clin Pharm       Date:  2011-07-22

3.  Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Authors:  Chandeshwar P Thakur; A Kumar; Dipendra K Mitra; Ambak Roy; Arun Kumar Sinha; Alok Ranjan
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

4.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

5.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

8.  Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.

Authors:  Swati Pal; Rajesh Ravindran; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis.

Authors:  Pouran Layegh; Omid Rajabi; Mahmoud Reza Jafari; Parisa Emamgholi Tabar Malekshah; Toktam Moghiman; Hami Ashraf; Roshanak Salari
Journal:  J Parasitol Res       Date:  2011-11-24

Review 10.  Therapeutic options for visceral leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.